Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS
- 21 March 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in Endocrine Research
- Vol. 42 (4), 261-268
- https://doi.org/10.1080/07435800.2017.1294602
Abstract
Purpose: Impaired β-cell function remains unaddressed in PCOS. The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR. Materials and methods: In 12-week randomized study, ALO 25 mg QD (n=15) or ALO 25 mg QD and PIO 30 mg QD (n=15) was added to MET 1000 mg BID in PCOS women (aged 34.4 ± 6.5 years, BMI 39.0 ± 4.9 kg/m2, HOMA-IR 4.82 ± 2.52, mean ± SD). Model derived parameters of glucose homeostasis from the meal tolerance test (MTT) were determined. The ability of the β-cell function was assessed by the adaptation index (AI). Results: MET-ALO and MET-ALO-PIO resulted in a significant decrease of HOMA-IR (by 1.6±2.3 (p=0.039) and 2.9±3.3 (p=0.001), respectively) and an increase in insulin sensitivity (IS) after meal ingestion (oral glucose IS) by 31.4±97.5 ml·min–1·m–2 (p=0.007) vs 39.0±58.1 ml·min–1·m–2 (p=0.039), respectively. AI across the entire group was significantly improved from 329.6±200.6 to 442.5±303.9 (p=0.048). Conclusions: ALO alone and in combination with PIO improved IR along with dynamic IS and meal related β-cell function when added to MET treated PCOS.Keywords
Funding Information
- Ministry of Health, Republic of Slovenia (20120047)
This publication has 34 references indexed in Scilit:
- Is there a place for incretin therapies in obesity and prediabetes?Trends in Endocrinology & Metabolism, 2013
- Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2012
- Should all women with PCOS be treated for insulin resistance?Fertility and Sterility, 2012
- Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidenceDiabetes, Obesity and Metabolism, 2011
- Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 DiabetesDiabetes Care, 2010
- Actos Now for the prevention of diabetes (ACT NOW) studyBMC Endocrine Disorders, 2009
- A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndromeFertility and Sterility, 2009
- Metabolic and Hormonal Changes Induced by Pioglitazone in Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Clinical TrialJournal of Clinical Endocrinology & Metabolism, 2009
- Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone TreatmentDiabetes Care, 2008
- Progression From Newly Acquired Impaired Fasting Glusose to Type 2 DiabetesDiabetes Care, 2007